Next Science (ASX:NXS) Debt-to-Equity: -9.51 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NXS Next Science Ltd ASX:NXS
25 GF Score
Price A$0.15
GF Value A$37.70
! 7 Warning Signs
View Full Analysis

What is Next Science Debt-to-Equity?

Next Science ASX:NXS 25 Debt-to-Equity is -9.51 as of Jun. 2025. GuruFocus rates ASX:NXS with a GF Score™ of 25/100 and a GF Value™ of A$37.70. The stock has 7 warning signs investors should review.

Next Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was A$0.41 Mil. Next Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was A$7.73 Mil. Next Science's Total Stockholders Equity for the quarter that ended in Jun. 2025 was A$-0.86 Mil. Next Science's debt to equity for the quarter that ended in Jun. 2025 was -9.51.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Next Science's Debt-to-Equity or its related term are showing as below:

ASX:NXS' s Debt-to-Equity Range Over the Past 10 Years
Min: -442.41   Med: 0.03   Max: 0.72
Current: -9.52

During the past 7 years, the highest Debt-to-Equity Ratio of Next Science was 0.72. The lowest was -442.41. And the median was 0.03.

ASX:NXS's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28 vs ASX:NXS: -9.52

Next Science  (ASX:NXS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Next Science Debt-to-Equity Related Terms

Next Science Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Next Science's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Next Science Debt-to-Equity Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial 0.02 0.03 0.15 0.08 0.72

Next Science Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -448.24 0.08 0.12 0.72 -9.51

ASX:NXS vs GCAN, PTPI, GRPS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Next Science's Debt-to-Equity falls into.


ASX:NXS
25GF Score
Next Science Ltd ASX:NXS
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Next Science Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Next Science's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.351 + 3.586) / 5.435
=0.72

Next Science's Debt to Equity Ratio for the quarter that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.41 + 7.734) / -0.856
=-9.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -9.51 mean?
Next Science (ASX:NXS) has a Debt-to-Equity of -9.51 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Next Science and its competitors.
Is Next Science's Debt-to-Equity too high?
Next Science's current Debt-to-Equity is -9.51. Overall, Next Science has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Next Science's Debt-to-Equity compare to GCAN and PTPI?
Next Science's Debt-to-Equity of -9.51 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Next Science and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Next Science's current Debt-to-Equity is -9.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (ASX:NXS) has a current Debt-to-Equity of -9.51. The stock's GF Value™ is A$37.70, compared to a current price of A$0.15 — trading 99.6% below its estimated fair value. The current Debt-to-Equity is -9.51. Next Science's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Next Science (ASX:NXS), the current Debt-to-Equity is -9.51 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Next Science (ASX:NXS) Overvalued in 2026?

Based on GuruFocus' analysis, Next Science stock appears to be undervalued. The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.

Key valuation signals for ASX:NXS:

  • Debt-to-Equity: -9.51
  • GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Next Science Business Description

Address 264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score

Get the complete analysis for ASX:NXS

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price
A$37.70
GF Value